Lsv Asset Management Puma Biotechnology, Inc. Transaction History
Lsv Asset Management
- $43.3 Billion
- Q4 2024
A detailed history of Lsv Asset Management transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 53,400 shares of PBYI stock, worth $147,918. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,400
Previous 30,400
75.66%
Holding current value
$147,918
Previous $78,000
108.97%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PBYI
# of Institutions
107Shares Held
32.2MCall Options Held
43.4KPut Options Held
3.7K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$9.9 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$8.48 Million0.42% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.45MShares$6.79 Million6.49% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.46 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $126M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...